BIOSGN — Biosergen AB Balance Sheet
0.000.00%
Last trade - 00:00- SEK85.01m
- SEK62.29m
Annual balance sheet for Biosergen AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | |
| Standards: | SAS | SAS | SAS | SAS | — |
| Status: | Final | Final | Final | Final | fx Preliminary |
| Cash | |||||
| Cash and Short Term Investments | 21.7 | 29.3 | 1.88 | 50.6 | — |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 3.17 | 1.49 | 0.342 | 0.492 | — |
| Prepaid Expenses | |||||
| Total Current Assets | 29.5 | 33.8 | 7.2 | 53 | — |
| Total Assets | 29.5 | 33.8 | 7.2 | 53 | — |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 9.25 | 11 | 5.08 | 4.81 | — |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 9.25 | 11 | 5.08 | 4.81 | — |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 20.2 | 22.8 | 2.12 | 48.2 | — |
| Total Liabilities & Shareholders' Equity | 29.5 | 33.8 | 7.2 | 53 | — |
| Total Common Shares Outstanding |